News

April, 10. 2016

Christian Reinhardt receives the Theodor Frerichs Award of the German Society for Internal Medicine

The 2016 Theodor Frerichs Research Award was presented to Christian Reinhardt on Sunday April 10th at the annual Meeting of the German Society for Internal Medicine in Mannheim.

Christian Reinhardt receives the Theodor Frerichs Award of the German Society for Internal Medicine
January, 10. 2014

ERC Consolidator Grant awarded to Cologne: New insights into aging- associated diseases

Prof. Thorsten Hoppe has received a prestigious ERC consolidator grant for his exceptional work on protein quality control.

ERC Consolidator Grant awarded to Cologne: New insights into aging- associated diseases
October, 16. 2013

Presentation of the Binet-Rai Medal for outstanding contribution to CLL research.

On September 10th, Prof. Michael Hallek was awarded with the Binet-Rai Medal for his outstanding contribution to CLL research over the last years. The Binet-Rai Medal was presented during the 15th international workshop on CLL, held in Cologne.

Presentation of the Binet-Rai Medal for outstanding contribution to CLL research.
October, 15. 2013

As a result of translational efforts of the Clinical Research Unit-286, a novel clinical trial for our CLL patients could be launched in Cologne.

The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR inhibitors) in patients with advanced CLL unresponsive to standard therapies and to determine the appropriate dosing level and regimen for later-stage clinical trials (NCT01353625). The medication will be taken orally. As a result of consequent translational efforts, we are now able to recruit genetically-stratified CLL patients into this trial. The molecular rationale for this novel treatment regimen was devised by scientists of our clinical research unit-286 (Riabinska et al., 2013). For any questions regarding this trial, please contact either Christian Reinhardt or Barbara Eichhhorst, who is serving as our leading clinical investigator.

As a result of translational efforts of the Clinical Research Unit-286, a novel clinical trial for our CLL patients could be launched in Cologne.